News | November 05, 2024
Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
CSPC will receive an upfront payment of $100 million from AstraZeneca
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Subscribe To Our Newsletter & Stay Updated
